Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCR: Anti-PD-1 + Chidamide + Rituximab in R/R DLBCL
NCT05115409Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of tucidinostat in diffuse large B-cell lymphoma (DLBCL), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05115409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05115409.